UA59394C2 - Стійка у фіксованих дозах оральна фармацевтична композиція, що містить антибактеріальний засіб і мікроорганізм одночасно, та спосіб її одержання (варіанти) - Google Patents

Стійка у фіксованих дозах оральна фармацевтична композиція, що містить антибактеріальний засіб і мікроорганізм одночасно, та спосіб її одержання (варіанти) Download PDF

Info

Publication number: UA59394C2
Authority: UA; Ukraine
Prior art keywords: approximately; microorganisms; antibacterial agent; pharmaceutical composition; composition according
Prior art date: 1998-03-04

Application number

UA99116272A

Other languages

English (en)

Russian (ru)

Ukrainian (uk)

Inventor

Раджів Індравадан Моді

Ятіш Кумар Бансал

Бакулеш Мафатлал Хамар

Original Assignee

Каділа Фармацевтікелс (І.Ей) Лтд.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-27

Filing date

1998-03-04

Publication date

2003-09-15

1998-03-04 Application filed by Каділа Фармацевтікелс (І.Ей) Лтд. filed Critical Каділа Фармацевтікелс (І.Ей) Лтд.

1998-03-27 Priority claimed from GBGB9806489.2A external-priority patent/GB9806489D0/en

2003-09-15 Publication of UA59394C2 publication Critical patent/UA59394C2/uk

Links

244000005700 microbiome Species 0.000 title claims abstract description 89
239000000203 mixture Substances 0.000 title claims abstract description 33
239000004480 active ingredient Substances 0.000 title claims abstract description 30
238000000034 method Methods 0.000 title claims abstract description 20
230000008569 process Effects 0.000 title abstract description 5
229960005475 antiinfective agent Drugs 0.000 title abstract 10
239000004599 antimicrobial Substances 0.000 title abstract 10
239000003826 tablet Substances 0.000 claims abstract description 36
239000011248 coating agent Substances 0.000 claims abstract description 24
238000000576 coating method Methods 0.000 claims abstract description 23
239000002775 capsule Substances 0.000 claims abstract description 18
229960003022 amoxicillin Drugs 0.000 claims abstract description 17
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims abstract description 17
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims abstract description 17
230000004888 barrier function Effects 0.000 claims abstract description 16
LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 claims abstract description 13
229960003326 cloxacillin Drugs 0.000 claims abstract description 13
230000000694 effects Effects 0.000 claims abstract description 12
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims abstract description 6
229960003276 erythromycin Drugs 0.000 claims abstract description 3
239000003242 anti bacterial agent Substances 0.000 claims description 97
239000008194 pharmaceutical composition Substances 0.000 claims description 26
239000008187 granular material Substances 0.000 claims description 25
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
239000000945 filler Substances 0.000 claims description 17
229960000723 ampicillin Drugs 0.000 claims description 14
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 14
238000004519 manufacturing process Methods 0.000 claims description 14
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
239000000725 suspension Substances 0.000 claims description 10
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
229940106164 cephalexin Drugs 0.000 claims description 6
ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 6
235000019359 magnesium stearate Nutrition 0.000 claims description 6
229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
239000008108 microcrystalline cellulose Substances 0.000 claims description 6
229920002472 Starch Polymers 0.000 claims description 5
229920002678 cellulose Polymers 0.000 claims description 5
239000001913 cellulose Substances 0.000 claims description 5
235000010980 cellulose Nutrition 0.000 claims description 5
239000008107 starch Substances 0.000 claims description 5
235000019698 starch Nutrition 0.000 claims description 5
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
239000007942 layered tablet Substances 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
229930186147 Cephalosporin Natural products 0.000 claims description 3
HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 3
229930182555 Penicillin Natural products 0.000 claims description 3
229940124587 cephalosporin Drugs 0.000 claims description 3
150000001780 cephalosporins Chemical class 0.000 claims description 3
229960003324 clavulanic acid Drugs 0.000 claims description 3
HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 3
150000002960 penicillins Chemical class 0.000 claims description 3
230000001681 protective effect Effects 0.000 claims description 3
239000008213 purified water Substances 0.000 claims description 3
239000011780 sodium chloride Substances 0.000 claims description 3
KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 claims description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
239000001856 Ethyl cellulose Substances 0.000 claims description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
239000002202 Polyethylene glycol Substances 0.000 claims description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
239000003781 beta lactamase inhibitor Substances 0.000 claims description 2
229940126813 beta-lactamase inhibitor Drugs 0.000 claims description 2
229960004841 cefadroxil Drugs 0.000 claims description 2
NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 claims description 2
229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
229940075614 colloidal silicon dioxide Drugs 0.000 claims description 2
235000019325 ethyl cellulose Nutrition 0.000 claims description 2
229920001249 ethyl cellulose Polymers 0.000 claims description 2
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 2
239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
239000008203 oral pharmaceutical composition Substances 0.000 claims description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 2
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
239000004408 titanium dioxide Substances 0.000 claims description 2
239000002966 varnish Substances 0.000 claims description 2
230000015572 biosynthetic process Effects 0.000 claims 2
239000000969 carrier Substances 0.000 claims 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
150000005012 8-aminoquinolines Chemical class 0.000 claims 1
241000566146 Asio Species 0.000 claims 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
229920000881 Modified starch Polymers 0.000 claims 1
229960002620 cefuroxime axetil Drugs 0.000 claims 1
229960003405 ciprofloxacin Drugs 0.000 claims 1
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
229940041033 macrolides Drugs 0.000 claims 1
239000011777 magnesium Substances 0.000 claims 1
229910052749 magnesium Inorganic materials 0.000 claims 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
206010012735 Diarrhoea Diseases 0.000 abstract description 17
239000007788 liquid Substances 0.000 abstract description 11
230000001225 therapeutic effect Effects 0.000 abstract description 9
238000002360 preparation method Methods 0.000 abstract description 6
239000002552 dosage form Substances 0.000 abstract description 5
239000002253 acid Substances 0.000 abstract description 2
229960001668 cefuroxime Drugs 0.000 abstract description 2
JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 abstract description 2
208000004840 megacolon Diseases 0.000 abstract description 2
208000018522 Gastrointestinal disease Diseases 0.000 abstract 4
230000002265 prevention Effects 0.000 abstract 2
206010009657 Clostridium difficile colitis Diseases 0.000 abstract 1
208000003100 Pseudomembranous Enterocolitis Diseases 0.000 abstract 1
206010037128 Pseudomembranous colitis Diseases 0.000 abstract 1
239000007963 capsule composition Substances 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000012669 liquid formulation Substances 0.000 abstract 1
239000007916 tablet composition Substances 0.000 abstract 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 70
241000894006 Bacteria Species 0.000 description 40
235000014655 lactic acid Nutrition 0.000 description 35
239000004310 lactic acid Substances 0.000 description 35
229940126601 medicinal product Drugs 0.000 description 17
239000004615 ingredient Substances 0.000 description 15
239000003814 drug Substances 0.000 description 8
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 6
229940079593 drug Drugs 0.000 description 6
229940088710 antibiotic agent Drugs 0.000 description 5
244000000010 microbial pathogen Species 0.000 description 5
238000011282 treatment Methods 0.000 description 5
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 4
229960002129 cefixime Drugs 0.000 description 4
OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
230000009931 harmful effect Effects 0.000 description 4
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
230000035899 viability Effects 0.000 description 4
229920002845 Poly(methacrylic acid) Polymers 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
229960003870 bromhexine Drugs 0.000 description 3
OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 3
206010009887 colitis Diseases 0.000 description 3
206010013023 diphtheria Diseases 0.000 description 3
AQOSPGCCTHGZFL-UHFFFAOYSA-N 1-(3a-hydroxy-7-methoxy-1,2,4,8b-tetrahydropyrrolo[2,3-b]indol-3-yl)ethanone Chemical compound COC1=CC=C2NC3(O)N(C(C)=O)CCC3C2=C1 AQOSPGCCTHGZFL-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
-1 B-12 Substances 0.000 description 2
241000186000 Bifidobacterium Species 0.000 description 2
SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
101000985278 Escherichia coli 5-carboxymethyl-2-hydroxymuconate Delta-isomerase Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
102100040448 Leukocyte cell-derived chemotaxin 1 Human genes 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 2
241000235342 Saccharomycetes Species 0.000 description 2
229940059273 amoxicillin 150 mg Drugs 0.000 description 2
229940048479 ampicillin 250 mg Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
230000002924 anti-infective effect Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
229960004399 carbocisteine Drugs 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000007888 film coating Substances 0.000 description 2
238000009501 film coating Methods 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000006194 liquid suspension Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
QPNHNCISNUAHNE-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;trimethylazanium;chloride Chemical compound [Cl-].C[NH+](C)C.COC(=O)C(C)=C QPNHNCISNUAHNE-UHFFFAOYSA-N 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
RLYOPPJABLAKCZ-UHFFFAOYSA-N 2-butoxycarbonylbenzenecarboperoxoic acid Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OO RLYOPPJABLAKCZ-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000030013 Poga Species 0.000 description 1
101710072850 Poxin Proteins 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
206010042566 Superinfection Diseases 0.000 description 1
108010053950 Teicoplanin Proteins 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940086793 amoxicillin 250 mg Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229960004755 ceftriaxone Drugs 0.000 description 1
VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
229940085929 cephalexin 250 mg Drugs 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
229960002227 clindamycin Drugs 0.000 description 1
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
239000007931 coated granule Substances 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
230000007797 corrosion Effects 0.000 description 1
238000005260 corrosion Methods 0.000 description 1
239000004148 curcumin Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940124307 fluoroquinolone Drugs 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000005461 lubrication Methods 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
238000013048 microbiological method Methods 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003973 paint Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
238000011158 quantitative evaluation Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 1
229950001870 spizofurone Drugs 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
229960001608 teicoplanin Drugs 0.000 description 1
239000011721 thiamine Substances 0.000 description 1
235000019157 thiamine Nutrition 0.000 description 1
201000002516 toxic megacolon Diseases 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1
239000005019 zein Substances 0.000 description 1
229940093612 zein Drugs 0.000 description 1
229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Natural Medicines & Medicinal Plants (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Botany (AREA)
Medical Informatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

UA99116272A 1998-03-27 1998-03-04 Стійка у фіксованих дозах оральна фармацевтична композиція, що містить антибактеріальний засіб і мікроорганізм одночасно, та спосіб її одержання (варіанти) UA59394C2 (uk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
LK1644598		1998-03-27
GBGB9806489.2A GB9806489D0 (en)	1998-03-27	1998-03-27	The process for the preparation of a stable fixed dose pharmaceutical composition of anti-infective agent/agents and micro organisms as active ingredients
PCT/IB1998/000445 WO1999049875A1 (en)	1998-03-27	1998-04-03	The process for the preparation of a stable fixed dose pharmaceutical composition of anti infective agent/agents and micro organisms as active ingredients

Publications (1)

Publication Number	Publication Date
UA59394C2 true UA59394C2 (uk)	2003-09-15

Family

ID=26313367

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA99116272A UA59394C2 (uk)	1998-03-27	1998-03-04	Стійка у фіксованих дозах оральна фармацевтична композиція, що містить антибактеріальний засіб і мікроорганізм одночасно, та спосіб її одержання (варіанти)

Country Status (9)

Country	Link
EP (1)	EP0998295A1 (id)
JP (1)	JP2002516616A (id)
AP (1)	AP9901724A0 (id)
AU (1)	AU770024B2 (id)
CA (1)	CA2291780A1 (id)
EA (1)	EA002148B1 (id)
ID (1)	ID26341A (id)
UA (1)	UA59394C2 (id)
WO (1)	WO1999049875A1 (id)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8227235B2 (en) *	2008-12-10	2012-07-24	Alpharma, Llc	Compositions and methods for controlling diseases in animals
GB0916335D0 (en) *	2009-09-17	2009-10-28	Martin W J	Medicaments
US20130131033A1 (en) *	2010-01-13	2013-05-23	Toyochem Laboratories	Pharmaceutical composition for treatment of respiratory tract infections
US11554112B2 (en)	2018-06-07	2023-01-17	Herum Therapeutics International Limited	Combinations of β-lactam compounds and probenecid and uses thereof
MX2021009755A (es) *	2019-02-13	2021-11-17	Iterum Therapeutics International Ltd	Combinaciones de compuestos beta-lactámicos y probenecid, y usos de los mismos.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8703360L (sv) *	1987-08-31	1989-03-01	Lejus Medical Ab	Granulaera produkter (iii)

1998
- 1998-03-04 UA UA99116272A patent/UA59394C2/uk unknown
- 1998-04-03 EP EP98909680A patent/EP0998295A1/en not_active Withdrawn
- 1998-04-03 AP APAP/P/1999/001724A patent/AP9901724A0/en unknown
- 1998-04-03 WO PCT/IB1998/000445 patent/WO1999049875A1/en not_active Ceased
- 1998-04-03 CA CA002291780A patent/CA2291780A1/en not_active Abandoned
- 1998-04-03 ID IDW991648A patent/ID26341A/id unknown
- 1998-04-03 AU AU64156/98A patent/AU770024B2/en not_active Ceased
- 1998-04-03 JP JP54906699A patent/JP2002516616A/ja not_active Ceased
- 1998-04-03 EA EA199900938A patent/EA002148B1/ru not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2291780A1 (en)	1999-10-07
WO1999049875A1 (en)	1999-10-07
AU770024B2 (en)	2004-02-12
AU6415698A (en)	1999-10-18
AP9901724A0 (en)	1999-12-31
EA002148B1 (ru)	2001-12-24
ID26341A (id)	2000-12-14
EP0998295A1 (en)	2000-05-10
JP2002516616A (ja)	2002-06-04
EA199900938A1 (ru)	2000-08-28

Publication	Publication Date	Title
FI90393B (fi)	1993-10-29	Menetelmä oraalisen, farmaseuttisen valmisteen valmistamiseksi, joka on pysyvä värin muuttumista vastaan
RU2681315C2 (ru)	2019-03-06	Лекарственные формы для пероральной доставки адсорбентов в кишечник
JP3622975B2 (ja)	2005-02-23	アモキシリンおよびクラブラン酸塩からなるポリマー被覆錠
KR100509351B1 (ko)	2005-08-22	복합 치료에 사용되는 유효 성분 투여용 이중 캡슐
IE58278B1 (en)	1993-08-25	Long-acting formulation of cefaclor
JPH0469333A (ja)	1992-03-04	大腸内放出性固形製剤
KR19990022220A (ko)	1999-03-25	의료 용도의 미소-캡슐화된 락토바실러스
US9028866B2 (en)	2015-05-12	Methods and compositions for oral pharmaceutical therapy
AU2010223233A1 (en)	2011-10-06	Compositions and methods for elimination of Gram-negative bacteria
US6306391B1 (en)	2001-10-23	Preparation of an oral pharmaceutical formulation containing an anti-infective agent and a microorganism
CA3236068A1 (en)	2019-01-17	Dual release dosage form capsule and methods, devices and systems for making same
US8299052B2 (en)	2012-10-30	Pharmaceutical compositions and methods for improved bacterial eradication
CS208196B2 (en)	1981-08-31	Method of making the perorally applicable preparation with the retarded liberation of the cefalexine as the active component
US20230233515A1 (en)	2023-07-27	Photodynamic anti-gram-positive bacterial activity of pharmaceutical-grade rose bengal
UA59394C2 (uk)	2003-09-15	Стійка у фіксованих дозах оральна фармацевтична композиція, що містить антибактеріальний засіб і мікроорганізм одночасно, та спосіб її одержання (варіанти)
Elkhodairy et al.	2014	A promising approach to provide appropriate colon target drug delivery systems of vancomycin HCL: pharmaceutical and microbiological studies
US20070134327A1 (en)	2007-06-14	Compositions and methods for improved efficacy of penicillin-type antibiotics
GB2323532A (en)	1998-09-30	Pharmaceutical compositions containing an anti-infective agent and a micro-organsim as active ingredients
US20020025309A1 (en)	2002-02-28	Stable oral pharmaceutical formulation containing an anti-infective agent and a microorganism
CN104523693A (zh)	2015-04-22	一种包含绿原酸的抗真菌复方制剂及其应用
AU2006321782B2 (en)	2012-11-29	Pharmaceutical compositions and methods for improved bacterial eradication
Nanda et al.	0	Formulation and Evaluation of Tinidazole, Probiotics and Prebiotic Oral Dosage Form
Abraham	2005	Development of Colon Specific Drug Delivery System for a Model Anti-Protozoal Drug